To the research team working to save him, KJ Muldoon was first known only as Patient Eta. But within months, KJ’s name — and ...

Casgevy, now a "national priority" drug, helped kids with sickle cell and thalassemia, results which may help toward a label ...

CRISPR Gene editing therapy is used for the first time in living humans with amazing results. Trump is guilty of mortgage ...

CRISPR Therapeutics recently drew attention as updates highlighted progress in its gene-editing pipeline, including early-stage studies of CTX310, an in vivo therapy designed to lower LDL cholesterol ...

Chicago-based CRISPR technology company Syntax Bio says it has developed tech which automates the slow, manual process of ...

Gene therapy could be a permanent cure for many life-threatening hereditary diseases, and this will only help in the treatment of genetic diseases and cancer ...

Despite a challenging CASGEVY launch, high cash burn, and an almost 10% YTD share count growth, CRISPR’s pipeline breadth and ...

If you have been wondering whether CRISPR Therapeutics at around $57 a share is a bargain or a bubble, you are not alone. This stock sits at the crossroads of high science and high expectations. The ...

A single CRISPR infusion lowered harmful cholesterol and triglycerides by nearly half in early trial results. Although this was a small trial, early safety findings are reassuring. Participants ...

Discover why Crispr Therapeutics AG is a strong buy with FDA-approved Casgevy, a promising pipeline, and major growth ...

The company will begin filing to global regulators in the first half of 2026. Read more at straitstimes.com. Read more at ...